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ABSTRACT. In this study, we report the development of the ﬁrst item response theory
(IRT) model within a pharmacometrics framework to characterize the disease progression in
multiple sclerosis (MS), as measured by Expanded Disability Status Score (EDSS). Data
were collected quarterly from a 96-week phase III clinical study by a blinder rater, involving
104,206 item-level observations from 1319 patients with relapsing-remitting MS (RRMS),
treated with placebo or cladribine. Observed scores for each EDSS item were modeled
describing the probability of a given score as a function of patients’ (unobserved) disability
using a logistic model. Longitudinal data from placebo arms were used to describe the disease
progression over time, and the model was then extended to cladribine arms to characterize
the drug effect. Sensitivity with respect to patient disability was calculated as Fisher
information for each EDSS item, which were ranked according to the amount of information
they contained. The IRT model was able to describe baseline and longitudinal EDSS data on
item and total level. The ﬁnal model suggested that cladribine treatment signiﬁcantly slows
disease-progression rate, with a 20% decrease in disease-progression rate compared to
placebo, irrespective of exposure, and effects an additional exposure-dependent reduction in
disability progression. Four out of eight items contained 80% of information for the given
range of disabilities. This study has illustrated that IRT modeling is speciﬁcally suitable for
accurate quantiﬁcation of disease status and description and prediction of disease progression
in phase 3 studies on RRMS, by integrating EDSS item-level data in a meaningful manner.
KEY WORDS: cladribine tablets; disease progression model; expanded disability status scale; item
response theory; multiple sclerosis.
INTRODUCTION
Multiple sclerosis (MS) is a chronic inﬂammatory and
neurodegenerative disease of the central nervous system (1). MS
affectsover1millionpeopleworldwide,andit is the leadingcauseof
non-traumatic disability in young adults (2). Over 80% of all
patients present with relapsing-remitting MS (RRMS), which is
characterized by unpredictable acute episodes of neurological
dysfunction named relapses, followed by variable recovery and
periods of clinical stability.
TheheterogeneityoftheMSpatientpopulationandcomplexity
of its clinical course have offered challenges to the quantiﬁcation of
disease severity and progression. The clinical manifestations of the
diseaseareextremelyvariable,even inanindividualpatient, ranging
from motor and sensory problems to cognitive and affective
disorders, which renders it necessary to use multidimensional
outcomemeasures.
Since the 1960s,many scales for rating disability caused byMS
havebeenproposed,butnonehasbeenentirely satisfactory(3).The
KurtzkeExpandedDisabilityStatusScale(EDSS)remains themost
widely used scoring system inMS. Its assessment is based on seven
functionalsystemsincludingvision,brainstem,pyramidal,cerebellar,
sensory,bowelandbladder,mental (cerebral),andambulation(500-
m walk), and reliance on aid. The EDSS is a summarized measure
which ranges from0(normalneurological exam) to10 (deathdue to
MS) in incremental steps of 0.5 (4). Despite its wide use and
acceptance, thereare several perceivedproblemswith theuseof the
scale, suchas limited inter-rater reproducibility,bimodaldistribution
of the scale, and potentially unequal steps, mostly due to its ordinal
nature(5,6). Itsoverall score isgreatlyweightedtowardambulation,
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especially in higher scores (EDSS> 3.5) (7) and is rather insensitive
to cognitive or upper limb dysfunctions. It is important to note that
EDSSitself israrelyusedasaclinicalendpoint inMSclinical trial,but
rather the EDSS-related endpoint: time to sustained EDSS
progression.
Quantifying the disease severity in MS is important to
monitor individual patients during their treatment and for
evaluating experimental therapies in clinical trials. As increasing
numbers of treatment options become available, sensitive
clinical outcome measures that can detect small changes in
disability that reliably reﬂect long-term changes in disease
progression are required. Identifying effective treatments de-
pends upon the availability of outcome measures that exhibit
good sensitivity to rates of changes caused by the disease.
Traditionally, item response theory (IRT) models have
been applied in educational testing to measure ability or
proﬁciency and in psychological assessments to measure
personality traits (8). Also, health outcome researchers have
been employing IRT to questionnaire development, evalua-
tion, and reﬁnement (9). IRT is a statistical theory consisting
of mathematical models expressing the probability of the
particular response to a scale item as a function of an
underlying trait, here disability of a person (10). IRT models
are also referred to as latent trait models, because the latent
Bunobservable^ trait of interest cannot be measured directly
and is therefore assessed indirectly by scoring various items
constructed to measure that underlying domain. Traditional
scoring consists of summarizing all the information in one
composite score, which might lead to loss of information
captured in the individual item. The recent application of
IRT to Alzheimer’s disease has demonstrated that increased
precision in cognitive assessment can be achieved by not
only considering scores on item level, but also how those
items function and the amount of information they contain
for the studied population (11, 12).
Here, we report the development of the ﬁrst IRT model
within a NLME (non-linear mixed effect) framework in MS
therapeutic area. Analysis was based on the data from
CLARITY (CLAdRIbine Tablets treating multiple sclerosis
orallY) study where cladribine was found to reduce, as
compared to placebo, the risk of 3-month sustained progres-
sion, by 33 and 31% in the cladribine 3.5 and 5.25 mg/kg
groups, respectively (13). Giovannoni et al. have reported
that the administration of cladribine tablets have been found
to be also efﬁcient in regard to other studied clinical
endpoints: annualized relapse rate (primary endpoint), per-
centage of relapse-free patients, and occurrence of magnetic
resonance imaging (MRI) detected brain lesions. The current
work investigates the possibility of quantiﬁcation of MS
disease progression and of effect of cladribine tablets. We
also explore the information content of each item constituting
EDSS.
MATERIALS AND METHODS
Patients and Study Design
Data from the CLARITY clinical trial were included in
the analysis. CLARITY was a phase III randomized, multi-
center, double blind, parallel group, controlled study,
evaluating the efﬁcacy and safety of 3.5 and 5.25 mg/kg
cumulative doses of cladribine tablets over 96 weeks in
patients with RRMS. Enrolled subjects had a diagnosed
deﬁnite relapse-remitting form of multiple sclerosis, accord-
ing to the McDonald criteria (14). Outcome assessments
were conducted in identical fashion to all other major MS
clinical trials. The blind was maintained by utilizing a
treating physician who viewed clinical laboratory results,
and assessed adverse events and safety information. Patients
received neurological assessment at baseline and every
12 weeks thereafter for the duration of the study by an
independent blinded evaluating physician. The additional
details of the study protocol, subject characteristics, and
study results can be found in the original publication (13).
Modeling Methodology
Analyses were performed in the software NONMEM
7.2.0, and Laplacian estimation method was applied for
parameter estimation (15). The simulation-based diagnostics
were realized using computer-intensive statistical methods
available in the Perl-coded program PsN (16).
In addition to seven polychotomous items of func-
tional systems with internal ranking, EDSS comprises
measures of ambulation (0–500 m walk) and reliance on
aid (0, 1, 2). According to neurostatus deﬁnition
(www.neurostatus.net), it is the combination of ambulation
and reliance on aid that is affecting the determination of
EDSS and not one of those variables independently. This
was used as a rational for combining those two variables in
the IRT analysis. Thus, a polychotomous variable with 11
categories, called ambaid was deﬁned as following:
ambaid = 0: ambulation≥ 500 m and aid = 0; ambaid = 1:
300 m ≤ ambulation ≤ 499 m and aid = 0; ambaid = 2:
200 m ≤ ambulation ≤ 299 m and aid = 0; ambaid = 3:
100 m ≤ ambulation ≤ 199 m and aid = 0; ambaid = 4:
5 m≤ ambulation≤ 99 m and aid = 0 or ambulation≥
50 m and aid = 1 or ambulation > 120 m and aid = 2;
ambaid = 5: 10 m < ambulation ≤ 49 m and aid = 1 or
10 m≤ ambulation≤ 120 m and aid = 2; ambaid = 6: ambu-
lation≤ 5 m and use of standard wheelchair; ambaid = 7:
ambulation of few steps requiring aid to transfer and use
standard wheelchair with assistance or motorized wheel-
chair; ambaid = 8: patient is wheelchair bound and capable
of Bmany^ self-care; ambaid = 9: patient is bed bound and
capable of Bsome^ self-care; ambaid = 10: patient is bed
bound and not capable of any self-care.
The relationship between patients’ response to an
item and their level of disability, here called IRT
disability, was modeled as ordered categorical data, and
item characteristic curves (ICC) are used to quantify and
visualize it (17). Observed scores for each EDSS item
were modeled describing the probability of a given score
as a function of patients’ disability variable using a logistic
model:
P Yi j≥k
  ¼ e
a j Di−b j;kð Þ
1þ ea j Di−b j;kð Þ
With bj and aj representing a point along the ICC of item
j at which the probability of the positive response for a
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dichotomous item is 50% and the slope of the ICC at that
point, respectively, and Di representing unobserved IRT
disability of patient i. Cumulative probabilities for a score of
M categories were modeled according to following equations
(18):
P Yi j ¼ 0
  ¼ 1− P Yi j > 1
 
P Yi j ¼ k
  ¼ P Yi j≥k
 
− P Yi j≥kþ 1
 
P Yi j ¼M
  ¼ P Yi j≥M
 
Parameters aj and bj characterizing item speciﬁc param-
eters were modeled as ﬁxed effects, while the IRT disability D
was modeled as subject-speciﬁc random effect, assuming
normal distribution with a mean of zero and ﬁxed variance
of 1, meaning that 68% of the population will be within the
IRT disability range of (−1, 1). The assumed scale of D goes
from –∞ to +∞, and it is relative to the studied population
with a typical patient at baseline having an IRT disability of 0.
In the case when scores of an item were not occurring in the
available data, merging of scores with a closest observed
score was performed.
Model development was conducted in ﬁve sequential
steps: development of the baseline model; development of
disease progression model based on placebo data; develop-
ment of the exposure-response model based on data from
patients on cladribine treatment; development of the covar-
iate model; and model evaluation.
For the disease progression model, linear and non-linear
(e.g., power and asymptotic) relationships were explored to
describe the change in IRT disability over time. The disease
progression model was then ﬁxed to develop the exposure-
response model. Linear, Emax, and sigmoidal Emax models
were tested. Exposure-dependent and exposure-independent
drug effects on disease progression were tested. A surrogate
exposure measure based on cumulative dose (CumDose) and
creatinine clearance (CLcr) was used to drive the exposure-
response relationship (19):
Expsi ¼
CumDose Clcr median
Clcr
After the drug model was developed, all model param-
eters were re-estimated simultaneously based on all available
data.
Age and clinical covariates (disease duration and num-
ber of relapses in the preceding 12 months (EXNB)) were
evaluated for their potential to account for the variability in
baseline IRT disability and in slope of disease progression of
the full model described above, using a full random effect
models (FREM) approach (20). Covariates were introduced
as observed variables, and their distribution was modeled as
random effects. A full covariance matrix between random
effects for parameters and covariates was estimated together
with other model components. Coefﬁcients for covariate-
parameter relations were obtained from the ratio of covari-
ance between parameter and covariate variability to the
covariate variance.
Model discrimination between hierarchical models was
primarily numerical and based on the likelihood ratio test of
obtained objective function values (OFVs). For model
selection, a signiﬁcance level of p < 0.05 was used, with the
degrees of freedom being equal to the difference in the
number of parameters between two models.
Model evaluation was carried out through simulation-
based diagnostics, mainly visual predictive checks (VPCs).
Two hundred Monte Carlo simulation replicates of the
original dataset with 95% prediction intervals were gener-
ated. Simulations were performed both on item level and on
total score level. An algorithm was developed using the R
program (21), to derive the total EDSS scores from individual
item scores.
Calculation of Information Content
From the developed IRT model, the Fisher information
for estimating a patient’s IRT disability was calculated for
each item constituting EDSS as minus the expectation of the
second derivative of the log-likelihood. Subsequently, the
information content for each item was computed for the
studied population, and items were ranked according to the
amount of information they contained.
Based on obtained item ranking, it was investigated
whether a shorter version of the EDSS including only the
most informative items would be able to identify patients with
sustained progression equally well as the original scale. For
this purpose, sustained progression was deﬁned as a con-
ﬁrmed increase in EDSS after a period of at least 3 months
with the increase deﬁned in relation to the baseline, of ≥1.5
points if baseline EDSS was 0; ≥1 points if baseline EDSS
was ≥1.0 and ≤4.5; ≥0.5 point if baseline EDSS was ≥5.0
(22). IRT disability status was determined based on all or on
the subset of EDSS items, and then 200 simulations were
performed using the developed model. The proportions of
patients identiﬁed as progressing according to the original
and shorten EDSS form were compared.
RESULTS
A total of 104,206 item level observations from 1319
patients were included in this analysis. A summary of study
demographics is shown in Table I.
Model
Baseline Model
The ﬁnal baseline model contained eight ordered cate-
gorical submodels in which a total of 42-item speciﬁc
parameters were estimated (Supplemental Table 1). All
parameters were successfully estimated with low uncertainty
associated. The obtained ICCs are shown in Fig. 1, illustrating
that a person with higher IRT disability has a higher
probability of increased scores for each item. Noteworthy
are the low slope parameter of 0.49 for visual, meaning that a
large increase in IRT disability only yields a small increase in
the probability for an increased score on this item, and the
high slope parameter value of 3.5 for ambaid resulting in a
high discrimination power in IRT disability around the bi
value of each score in this item.
Figure 1 also highlights an expected score larger than 0
for the sensory, mental, and visual item for individuals
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considered healthy (IRT disability = −4); this can be ex-
plained by non-MS-related impairment of those functions, as
those are not MS-speciﬁc symptoms.
For most of the items, score of 0 is the most frequently
observed score. Also, the probability for a score of 0 drops
quickly as the IRT disability increases, except for ambaid item
where probability of having score of 0 remains 100% with
increasing IRT disability until a certain level of IRT disability
is reached. This is in line with common clinical knowledge
that only patients with advanced stage of the disease will start
experiencing impaired ambulation (EDSS higher than score
of 4).
Probability curves for different scores of some items
(e.g., mental) overlap over a range of IRT disability levels,
indicating that a speciﬁc item does not differentiate well
between those scores for a given range of IRT disability.
Figure in supplemental 1 shows that the frequency with
which the score is observed at baseline is captured within the
95% prediction interval of the model.
Figure 2 depicts the relationship between EDSS and the
corresponding IRT disability levels for each patient in the
dataset at baseline. This ﬁgure shows that although there is a
trend of increasing EDSS scores with increasing disease
states, each EDSS score corresponds to a wide spectrum of
underlying IRT disability scores and vice-versa.
Disease Progression Model Based on Placebo Data
Disease progression in patients receiving placebo treat-
ment was best described with a power model with an
estimated IRT disability at baseline (D0), disease progression
rate (α), and a power constant (pwr):
Di tð Þ ¼ D0;i þ αi  tpwr
A signiﬁcant positive correlation of 0.59 (p < 0.001) was
observed between baseline IRT disability and the disease
progression rate, indicating that patients with higher IRT
disability at baseline are likely to progress faster. Positive
slope of disease progression, signiﬁcantly different from zero
(p < 0.001) was estimated. The estimated disease progression
rates were on IRT disability scale. Simulations were also
performed which translates those results to the EDSS scale,
and according to these simulations, the typical patient in this
dataset receiving placebo treatment will progress 0.16 EDSS
points over 2 years.
Table I. Summary of Patient Baseline Characteristics
Variable CLARITY placebo CLARITY
cladribine 3.5 mg/kg
CLARITY
cladribine 5.25 mg/kg
Age—year
Median 38 38 39
Range 18–64 18–65 18–65
Body weight—kg
Median 69 66.1 66.9
Range 40–119.7 40–117 41.2–120
Sex no. (%)
Male 149 (34.3) 135 (31.4) 143 (31.5)
Female 286 (65.7) 295 (68.6) 311 (68.5)
Disease duration
Median 7.1 5.7 7.2
Range 0.4–39.5 0.3–42.3 0.4–35.2
Age of disease onset
Median 29.2 29.1 29.2
Range 7.7–55.9 7.9–57.6 5.8–57.9
EDSS
Median 3 2.5 3
Range 0–5.5 0–6 0–5.5
EXBN
Median 1 1 1
Range 1–5 1–5 0–5
EXBN annualized number of relapses 2 years prior to the study
Fig. 1. Item characteristic curves per item: probability of occurrence
of each score as a function of IRT disability at baseline (with positive
values of disability indicating a higher disability than the disability of
the typical patient)
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Exposure-Response Model
The disease progression as well as the drug effect in
patients receiving cladribine treatment was best described
according to the following equation:
Di tð Þ ¼ D0;i þ αi  tpwr  1−EffDð Þ− Emax ExpsiExps50 þ Expsi
with IRT disability at baseline (D0), disease progression
rate (α), power constant (pwr), maximal exposure-dependent
drug effect (Emax), exposure needed for half maximal effect
(Exps50), and constant exposure-independent drug effect
(EffD).
The effect of cladribine on IRT disability was best
described using both exposure-dependent and exposure-
independent drug effects. The ﬁnal model suggests that
cladribine treatment signiﬁcantly (p < 0.001) slows disease-
progression rate, with a 20% decrease in disease progression
rate compared to placebo, irrespective of exposure in the
investigated cumulative dose range (20–600 mg). The model
also describes an exposure dependent decrease in IRT
disability in patients treated with cladribine tablets with a
cumulative dose of 407 mg being needed for half maximal
(exposure-dependent) effect in a typical patient, which would
translate for a typical patient receiving a typical dose of
240 mg in 45% reduction of disease progression.
Covariate Model
Covariate analysis revealed that baseline IRT disability
was correlated with age, duration of disease, and EXNB by
coefﬁcients of 0.027, 0.037, and 0.075, respectively. This
means for instance that a typical patient of 58 years, who is
20 years older than the population’s mean of 38 years, will
have a baseline IRT disability that is 0.54 (i.e., 20*0.027) units
higher on the disability scale, then the IRT disability of a
typical patient with the mean age in this population. Similarly,
there is a 7.5% increase in baseline IRT disability per number
of relapses (>1) in the year previous to the study. Coefﬁcients
for covariates effects on the slope of disease progression were
0.0053, 0.0054, and 0.05 for age, duration of disease, and
EXNB, respectively.
Final parameter estimates for this model are shown in
Table II. RSE values in all model parameters were below
20%, meaning the parameters could be estimated from the
data with high certainty.
Model Evaluation
Simulations from the developed IRT model were per-
formed in order to demonstrate the predictive ability of the
ﬁnal model. The item level VPC, with the example of
brainstem item, in Fig. 3 shows that for the duration of the
trial there is a good agreement between observed and
predicted scores. VPCs for the remaining seven items can
be found in Supplemental 2. Moreover, Fig. 4 shows the
observed and model-predicted total EDSS scores coincide
over time for each treatment arm.
Calculation of Information Content
Fisher information content as a function of IRT disability
is shown for each item in Fig. 5. The shaded area indicates the
Fig. 2. Observed EDSS scores and estimates of IRT disability at
baseline
Table II. Population Parameter Estimates from the Final Model
Parameter estimates
(RSE%a)
Disease progression slope 0.087 (6.5)
Disease progression power 0.707 (3.6)
ω2 Slope 0.199 (6.9)
Emax exposure-dependent drug effect 0.171 (5.3)
ω2 Emax 2.20 (9.2)
Exp50 exposure-dependent drug effect 406.8 (4.8)
Constant exposure-independent drug effect 0.228 (4.5)
Correlation dis0/slope 0.113 (18.6)
aRelative standard errors from bootstrap (n = 100) in NONMEM
Fig. 3. Visual predictive checks (VPCs) describing the time-courses
of each score for the brainstem item. Median (blue solid line) of the
observed data is compared to the 95% prediction interval (gray
shaded area) for the simulated data
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interval of IRT disability containing 95% of the study
population. The information content varies considerably
across items as is evident from differences in the location of
the maxima of the information curves as well as differences in
their amplitude. As an item is most informative around its b
value, the most Bdifﬁcult^ parameter, ambaid, contains most
information concerning the highly disabled subgroup of
studied patients’ population.
Items were ranked based on their expected Fisher
information for the range of IRT disabilities in the current
study population. The cerebellar item was found to contain
most of information, followed by pyramidal and ambaid
items. As shown in Table III, four (cerebellar, pyramidal,
ambaid, bowel, and bladder) out of eight items contained
80% of information for the given range of IRT disabilities.
Noteworthy is the visual item that is found to contain least
information among EDSS items, which is also visualized by
the ﬂat ICCs for this item in Fig. 1.
From this, the EDSS4 scale, based only on the four
most informative items, was derived and then evaluated by
computing the ratios of patients classiﬁed as progressing
for EDSS4 (shortened version) and EDSS8 (original
version). Based on simulations, proportions of progressing
patients were very similar independent of used scale (95%
CI [0.92, 1.06]).
DISCUSSION
Using the data from a phase III clinical trial, IRT
methodology has been successfully implemented for the ﬁrst
time to model EDSS in patients with RRMS. The model
reported here was developed using data from a clinical trial
investigating the effect of cladribine tablets on RRMS. The
drug effect model is certainly speciﬁc to cladribine, but the
implementation of IRT methodology to EDSS as well as the
description of time-course of disease progression has broader
applicability, beyond cladribine tablets.
Traditional approaches to analyze questionnaire-based scales
generally disregard the underlying nature of the data and usually
regard only summary scores. In the past, EDSS has been modeled
either as a continuous variable (19) or as an ordered categorical
variable with considerable simpliﬁcation of the scale (20
categories combined into 5–6 categories) (23, 24). Instead
of modeling changes in the composite score over time,
application of IRT allows derivation of underlying/
unobserved latent variable from observed subscores and
model the changes in that latent variable over time. The
IRT methodology has been applied here to order categor-
ical data, but it has been shown by Ueckert et al. that it is
equally suitable for other types of non-continuous data,
such as binary or count data (12).
The effectiveness of therapeutic interventions can be
determined, only if accurate quantiﬁcation of disease severity
is possible. Central to the patient, the most important therapeu-
tic aim of any diseasemodifying treatment ofMS is to prevent or
postpone long-term disability. In phase III trials, various
surrogate measures such as relative reduction in annualized
relapse rate and risk of 3-month sustained progression have
been used as predictors for this disability, but there is limited
evidence that those changes reﬂect true irreversible accumula-
tion of disability at long-term scale (25). Both analyses of
CLARITY trial data, our IRT analysis of EDSS subitems and
traditional statistical analysis of time to sustained progression
have found that cladribine tablets have an effect on the studied
endpoints Bdisease progression^ and Brisk of 3-month sustained
progression of disability .^ However, using time to ﬁrst conﬁrmed
disability progression as an endpoint inMS clinical development
does not allow for a description of disease progression, as we
know that disability progression does not stop after the ﬁrst
event. In contrast, our model can be used to understand time-
course of disease and effect of the treatment, and a role of the
individual components of EDSS. It can also be used for clinical
trial simulations.
Fig. 5. Information content for EDSS items versus IRT disability. The
shaded areas indicate the disability range for 95% of studied population
Table III. Ranking of EDSS Components by Information Content in
Studied Population
Item Information % total Cumulative % total
Cerebellar 2.18 33.9 33.9
Pyramidal 1.62 25.3 59.2
Ambaid 1.14 17.8 77
Bowel and bladder 0.45 7 84
Brainstem 0.37 5.8 89.8
Cerebral 0.29 4.5 94.3
Sensory 0.28 4.4 98.7
Visual 0.08 1.2 100
Fig. 4. VPC for the ﬁnal model describing the change in EDSS vs time,
stratiﬁed by treatment arm. Median (blue solid line), 2.75th, and 97.25th
percentiles (blue dashed lines) of the observed data are compared to the
95% conﬁdence intervals for the simulated data’s 2.75th, 97.25th
percentiles (gray shaded areas), and median (red shaded area)
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Another aspect of the slowly progressing and highly variable
nature of the disease is that patients may remain at the same score
for a prolonged period of time. According to themodel developed
by Savic et al.(19) for instance, a typical patientwill experience 0.14
EDSS units increase in disease severity over 2 years on placebo
treatmentandonly0.024points increasewhentreatedwitha3.5mg/
kg cumulated dose of cladribine. Using IRT, disability may be
determinedmore accurately than with the composite EDSS score.
Results shown in Fig. 2 for instance reveal that each EDSS score
corresponds to a wide range of underlying IRT disabilities,
indicating that total scores are relatively imprecise measures of
underlying IRT disability. Better quantiﬁcation of disease severity
will also improve our assessment of disease progression and
treatment effect. Comparable results were obtained for ADAS-
cog score inAlzheimer’s disease (11).
Full EDSS assessment takes over 40 min to be performed
by a neurologist, hampering its use in everyday clinical practice.
Increased efﬁciency could be achieved with optimal selection of
the most informative subset of items. Here, we use Fisher
information as a measure of item information content as it
directly relates to the expected variance of the individual latent
variable estimates. Conceptually, we are able to choose the
items that have the largest signal to noise ratio, i.e., where a
functional change relates most directly to a change in disease
state. We have shown that 80% of the information about
underlying disease status in MS, in the studied population, is
quantiﬁed in only four of the eight EDSS items, namely
cerebellar, pyramidal, ambaid, and bowel and bladder. Simula-
tions have demonstrated that our proposed shortened scale
performs equally well as the full EDSS scale when it comes to
determining a clinically meaningful measure, the ratio of
patients experiencing a 3-month sustained progression. With
this example, we have just demonstrated how a rational
subselection of items can be made if one wants to simplify the
test. This could be taken even further by turning it into a
dynamic process—the answer to the ﬁrst item evaluation directs
which item to investigate next.
MS affects functional systems of the EDSS differently as
identiﬁed by Healy et al. (25). They have demonstrated that
the time to sustained progression varied widely across the
EDSS items; it was the fastest for the pyramidal and sensory
scales and the slowest for brainstem and visual scales.
Identiﬁcation of subgroups of patients more likely to experi-
ence substantial worsening of the disease, by focusing on
speciﬁc sensitive items, will increase the difference in drug
effect between groups, if one is in fact present. Thus, the
insight into information content on item level achieved
through IRT analysis could be used as a valuable tool, in
combination with other study enrichment strategies.
Despite its weaknesses, the extensive use of EDSS in
patients with RRMS is likely to be continued. Current
treatments have been authorized based on clinical trials using
EDSS as one of the endpoints, and EMA requires new
therapies to be compared to existing ones by using the same
outcome measures to demonstrate their effectiveness (26).
Also, on the individual patient level, there is a need for
continuity in use of outcome measures in order to ensure the
long-term records of disease severity (27). Moreover, the
clinical course of RRMS can vary tremendously, and it is
likely that different outcome measures are demanded
in different stages of the disease (3). Establishing and
quantifying the relationship between different outcome
measures has been proven challenging in the past (25, 28).
One of the ways to enable the direct comparison of
results obtained on different scales for disease severity would
be by the application of IRT. Ueckert et al. have demon-
strated the possibility of jointly analyzing different ADAS-
cog variants, without any recalculation or normalization of
measured scores. In the ﬁeld of MS, this approach could be
utilized to bridge between the diversity of scores that are used
for quantiﬁcation of disease progression, as IRT disability
levels of patients can be easily compared once outcome
measures on the different scales have been mapped to overall
IRT disability. This approach will also allow evaluation of
performance of one assessment method relative to another.
CONCLUSION
Accurate quantiﬁcation of disease status and description
and prediction of disease progression is essential for drug
development. For chronic diseases with slow progression such
as multiple sclerosis, this is especially pertinent, due to the
high costs of long-term clinical trials required to establish
treatment efﬁcacy. This study has illustrated that IRT
modeling is speciﬁcally suitable for this purpose in phase 3
studies on RRMS, by integrating EDSS item level data in a
meaningful manner instead of aggregating information by
deriving a composite score.
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